Commentary: Modulation of ASC-derived extracellular vesicles containing cargo that specifically enhances wound healing

Recent advances in extracellular vesicle (EV)-based therapeutics have highlighted their potential as biologically active mediators in tissue repair and regenerative pharmacology. In this context, the study by Gurney et al. (2025) presents a manufacturing-driven approach to generate functionally 'tuned' EVs for wound healing applications. Here, we provide a critical and constructive commentary focusing on interpretability, reproducibility, and translational considerations.The authors report a bioreactor-based strategy to manufacture "tuned" extracellular vesicles (EVs) from human adipose-derived stem cells (ASCs), termed eXo3, and benchmark these EVs against "native" EVs generated from the same ASC lot under traditional culture conditions (Gurney et al., 2025). The core premise that ex vivo environmental cues can reshape EV cargo and thereby shift functional potency toward a pro-healing phenotype addresses a practical bottleneck in regenerative pharmacology: how to preserve efficacy and consistency while minimizing phenotypic drift (including senescence-associated changes) in producer cells. The manuscript integrates EV characterization with functional in vitro assays in primary human skin-relevant cells, paired in vivo wound models, and a translational bridge via topical formulation and a single case observation in a chronic diabetic wound setting. Beyond acute wound closure, these questions also matter for inflammatory skin states where impaired repair and inflammation coexist (e.g., selected inflammatory skin contexts), where modulating inflammatory signaling can influence disease trajectory (Lee CH et al., 2022a).For clarity, we use "ASC-derived EVs" to refer to vesicles isolated from adipose-derived stem cells under defined culture conditions, whereas "native EVs" denote vesicles obtained under conventional culture without tuning. Where applicable, conditioned media-derived exosome preparations are explicitly distinguished as a separate comparator. Terminology is used consistently throughout.A notable contribution is the manufacturing-centric framing of EV potency. The authors highlight that a controlled hollow-fiber bioreactor environment can be leveraged to tune EV production and cargo packaging, positioning process parameters as actionable levers for improving bioactivity (Gurney et al., 2025). The characterization panel is recognizable and practical, including nanoparticle tracking analysis (ZetaView NTA), transmission electron microscopy (TEM), and surface marker profiling using the MACSPlex Exosome Kit (37 markers), complemented by BCAbased protein quantification. In a field where nomenclature, separation, and characterization rigor remain recurrent review points, a brief statement of alignment with MISEV-style reporting items would further support interpretability and reproducibility (Théry et al., 2018;Welsh et al., 2024).The parallel preparation of eXo3 and "native" EVs from the same ASC lot is a strength because it helps isolate the effect of manufacturing cues (Gurney et al., 2025). It may help readers if the manuscript briefly reiterates (at a high level) which bioreactor environmental features are modified for eXo3 versus native conditions and how these are controlled across runs.Clarifying whether the in vivo 'exosome preparation derived from adipocyte-conditioned media' is identical to the ASC-derived EVs described in Sections 2.1-2.2, or represents a distinct input, would materially improve traceability from manufacturing to outcomes. This single clarification would make it easier to map production inputs to downstream outcomes, and it would support the manuscript's emphasis on controlled manufacturing and product definition (Théry et al., 2018;Welsh et al., 2024).The in vitro panel is well aligned with key features of skin repair, capturing inflammatory cytokine modulation, migration, proliferation, and matrix output in primary human skin-relevant cells Stating this assay-to-endpoint mapping upfront would help readers interpret 'potency' as linked to defined healing phases rather than as a broad assay list.The excisional wound section includes several elements reviewers commonly value: standardized dorsal wounds, within-animal PBS vehicle controls, randomization across wound positions to reduce positional bias, and blinded assessment (Gurney et al., 2025). The use of daily wound measurement and photography for up to 30 days supports kinetic analysis and durability assessment.To strengthen biological interpretability, it would be useful to clarify whether the primary focus is surface closure kinetics, repair quality, or both. For closure kinetics, this could be stated explicitly as serial wound area reduction over time (e.g., time to 50% and complete closure). For repair quality, a minimal set of end-of-study readouts-such as re-epithelialization thickness/continuity, collagen organization (Masson's trichrome or picrosirius red), and a semi-quantitative inflammatory infiltrate score-would help distinguish faster closure from improved tissue maturation.A growing preclinical literature supports the concept that adipose-derived stem cell exosomes can accelerate wound healing and improve vascularization, collagen deposition, and reepithelialization, including in diabetic wound settings (Wei et al., 2024). Given this background, the present work's emphasis on manufacturing control and potency consistency is timely and potentially differentiating.At the same time, the manuscript's discussion of senescence and SASP-like drift is an important framing choice; recent literature has explicitly highlighted "senescent drift" risk as a quality and efficacy issue for MSC/ASC secretome-based therapeutics in skin wound repair (Smirnova et al., 2023). In that sense, additional short clarifications about how senescence is operationally monitored/avoided in the production pipeline would likely be received positively.The topical translation is of interest, particularly because eXo3 is incorporated into a hyaluronic acid-based gel for OTC personal care use, whereas PBS dilution is used for in vitro and animal assays (Gurney et al., 2025). In the single diabetic wound case observation, we recommend stating explicitly that this is hypothesis-generating and intended to illustrate translational feasibility rather than demonstrate efficacy. Where applicable, a brief note indicating that informed consent was obtained and whether standard-of-care measures or other co-interventions were continued would help readers interpret the case observation appropriately. One concise limitations sentence (e.g., no randomization/blinding, possible co-interventions/standard care changes, and natural fluctuation in chronic wounds) would preserve credibility while keeping the real-world signal visible.Overall, this study provides a timely and practically relevant contribution by connecting controlled bioreactor production of ASC-derived EVs with a practical potency and wound-healing evaluation package (Gurney et al., 2025). The study's impact could be further strengthened by minor reporting clarifications (particularly around comparator definitions and source terminology) along with tighter linkage between in vitro assays and in vivo endpoints and clearer specification of "healing" endpoints beyond closure. We offer a minimal checklist (Table 1) aligned to the methods and models used here, as a constructive tool to support reproducibility and facilitate evaluation of EV-based dermatologic repair claims. More broadly, establishing a rigorous potencyand-endpoint framework may help inform future, carefully controlled exploration of EV-based strategies in chronic inflammatory skin settings where impaired repair and immune dysregulation coexist, including atopic dermatitis-associated barrier dysfunction contexts (Lee et Clarifies what 'potency' means biologically.Briefly map in vitro readouts to in vivo endpoints (re-epithelialization, granulation/remodeling).Strengthens the potency-tohealing rationale.Report model details, randomization/blinding, treatment schedule/route; state whether outcomes emphasize closure kinetics, repair quality, or both (list core quality endpoints if assessed).Defines 'healing' and improves interpretability.Describe planimetry/imaging standardization; specify unit of analysis (wound vs animal) and handling of clustered/repeated measures.Translational claims For human observations, label as hypothesis-generating; report standard care/co-interventions and quantification approach.Limits over-claiming and preserves credibility.